The Impact and Unmet Needs Associated with Dementia-Related Psychosis

This publication is sponsored by Acadia Pharmaceuticals, Inc.

This Clinical Brief explores the prevalence and burden associated with dementia-related psychosis, underscoring a critical unmet need for effective therapy.

Download PDF

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

The Impact and Unmet Needs Associated with Dementia-Related Psychosis

Newsletter

Related Content

Quality of Life: The Pending Outcome in Idiopathic Pulmonary Fibrosis

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era